Anthony Nguyen, DO
Family Medicine · Mobile, ALNPI 1396157194
Payments from drug & device makers
What this record shows
This record is dominated by grants: $20,000 of the $20,378 with a category attached, or 98.1%. Medtronic accounts for 98.3% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2019 at $20,094 and has fallen 99.4% since, to $116 in 2025. Among family medicine clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 14 payments — averaging $1455.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$20K
- Novo Nordisk$169
- Reflow Medical Inc$116
- AstraZeneca$21
- Boston Scientific$16
- Genentech USA, Inc.$15
- plus $12 from 1 others
What the payments were for
- Grants$20,00098%
- Food & beverage$3782%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 4 | $20,029 |
| Novo Nordisk | 4 | $169 |
| Reflow Medical Inc | 2 | $116 |
| AstraZeneca | 1 | $21 |
| Boston Scientific | 1 | $16 |
| Genentech USA, Inc. | 1 | $15 |
| Pfizer | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SYNCHROMED$20,000
- Wegovy$125
How this compares
$20,378 in reported general payments places this provider in the 95th percentile of 1,680 family medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 87 | $96,822 |
| JardianceEmpagliflozin | 42 | $61,137 |
| OzempicSemaglutide | 27 | $57,473 |
| MounjaroTirzepatide | 29 | $38,526 |
| JanuviaSitagliptin Phosphate | 19 | $21,818 |
| EliquisApixaban | 15 | $19,954 |
| Tresiba Flextouch U-100Insulin Degludec | 16 | $12,987 |
| VascepaIcosapent Ethyl | 12 | $7,441 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 26 | $3,941 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $3,267 |
| Pregabalin | 21 | $3,213 |
| Humalog Kwikpen U-100Insulin Lispro | 11 | $2,963 |
| Rosuvastatin Calcium | 202 | $2,357 |
| Levothyroxine Sodium | 136 | $1,854 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 94 | $1,607 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $21 | $96,82287 claims |
| Novo NordiskOzempic | $169 | $57,47327 claims |
| PfizerEliquis | $12 | $19,95415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,680 family medicine providers in Alabama.
Other family medicine in Mobile
- Joel LaughlinMobile$75K
- Ashleigh Butts-WilkersonMobile$54K
- Mark WilesMobile$14K
- Lashelle BarmoreBirmingham$486K
- Regina BenjaminBayou la Batre$222K
- Jonathan ParkerMuscle Shoals$214K
- Kathleen DupperHuntsville$210K
- Whitney TewHuntsville$114K
- Kelly HunterTuscaloosa$84K
- Daniel EnglertHuntsville$82K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.